Bioverativ Inc (BIVV) - Financial and Strategic SWOT Analysis Review

March 2018 | 48 pages | ID: B691298A7D5EN
GlobalData

Abstracts

Bioverativ Inc (BIVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technology for the treatment of hemophilia A; and Alprolix, which comprises recombinant coagulation factor IX engineered using Fc fusion technology for the treatment of hemophilia B. The company’s pipeline encompasses investigational candidates for the treatment of cold agglutinin disease, hemophilia A, beta thalassemia sickle cell disease, hemophilia B, and Sickle cell disease. Bioverativ sells its products in the US, the European Union (EU), New Zealand, Canada, Australia, Japan, Switzerland, Iceland, Liechtenstein, and Norway. Bioverativ is headquartered in Waltham, Massachusetts, the US.

Bioverativ Inc Key Recent Developments

Feb 13,2018: Bioverativ Reports Fourth Quarter and Full Year 2017 Performance
Oct 26,2017: Bioverativ Reports Third Quarter 2017 Performance
Aug 02,2017: Bioverativ Reports Second Quarter 2017 Performance
Jul 06,2017: New Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care
May 15,2017: Bioverativ Appoints Geno J. Germano to Company’s Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Bioverativ Inc - Key Facts
Bioverativ Inc - Key Employees
Bioverativ Inc - Key Employee Biographies
Bioverativ Inc - Major Products and Services
Bioverativ Inc - History
Bioverativ Inc - Company Statement
Bioverativ Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Bioverativ Inc - Business Description
R&D Overview
Bioverativ Inc - Corporate Strategy
Bioverativ Inc - SWOT Analysis
SWOT Analysis - Overview
Bioverativ Inc - Strengths
Bioverativ Inc - Weaknesses
Bioverativ Inc - Opportunities
Bioverativ Inc - Threats
Bioverativ Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Bioverativ Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 13, 2018: Bioverativ Reports Fourth Quarter and Full Year 2017 Performance
Oct 26, 2017: Bioverativ Reports Third Quarter 2017 Performance
Aug 02, 2017: Bioverativ Reports Second Quarter 2017 Performance
Jul 06, 2017: New Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care
May 15, 2017: Bioverativ Appoints Geno J. Germano to Company’s Board of Directors
May 03, 2017: Bioverativ Reports First Quarter 2017 Results
Apr 10, 2017: Bioverativ Appoints Tim Harris Executive Vice President, Research and Development
Mar 02, 2017: Anna Protopapas to Join Bioverativ Board of Directors
Mar 02, 2017: Anna Protopapas to Join Bioverativ Board of Directors

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Bioverativ Inc, Key Facts
Bioverativ Inc, Key Employees
Bioverativ Inc, Key Employee Biographies
Bioverativ Inc, Major Products and Services
Bioverativ Inc, History
Bioverativ Inc, Other Locations
Bioverativ Inc, Subsidiaries
Bioverativ Inc, Key Competitors
Bioverativ Inc, Ratios based on current share price
Bioverativ Inc, Annual Ratios
Bioverativ Inc, Annual Ratios (Cont.1)
Bioverativ Inc, Annual Ratios (Cont.2)
Bioverativ Inc, Interim Ratios
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Bioverativ Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Bioverativ Inc, Performance Chart (2013 - 2017)
Bioverativ Inc, Ratio Charts
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Pfizer Inc
Novo Nordisk AS
Bayer AG